{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:26:27Z","timestamp":1790893587207,"version":"4.1.0"},"reference-count":43,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T00:00:00Z","timestamp":1691884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["PHRC\u2010K 2006"],"award-info":[{"award-number":["PHRC\u2010K 2006"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>We report the results of the French multicentric phase II study MIITOP (NCT00960739), which evaluated tandem infusions of <jats:sup>131<\/jats:sup>I\u2010metaiodobenzylguanidine (mIBG) and topotecan in children with relapsed\/refractory metastatic neuroblastoma (NBL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients received <jats:sup>131<\/jats:sup>I\u2010mIBG on day 1, with intravenous topotecan daily on days 1\u20135. A second activity of <jats:sup>131<\/jats:sup>I\u2010mIBG was given on day 21 to deliver a whole\u2010body radiation dose of 4\u00a0Gy, combined with a second course of topotecan on days 21\u201325. Peripheral blood stem cells were infused on day 31.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty patients were enrolled from November 2008 to June 2015. Median age at diagnosis was 5.5\u00a0years (2\u201320). Twenty\u2010one had very high\u2010risk NBL (VHR\u2010NBL), that is, stage 4 NBL at diagnosis or at relapse, with insufficient response (i.e., less than a partial response of metastases and more than three mIBG spots) after induction chemotherapy; nine had progressive metastatic relapse. Median Curie score at inclusion was 6 (1\u201326). Median number of prior lines of treatment was 3 (1\u20137). Objective response rate was 13% (95% confidence interval [CI]: 4\u201331) for the whole population, 19% for VHR\u2010NBL, and 0% for progressive relapses. Immediate tolerance was good, with nonhematologic toxicity limited to grade\u20102 nausea\/vomiting in eight patients. Two\u2010year event\u2010free survival was 17% (95% CI: 6\u201332). Among the 16 patients with VHR\u2010NBL who had not received prior myeloablative busulfan\u2010melphalan consolidation, 13 had at least stable disease after MIITOP; 11 subsequently received busulfan\u2010melphalan; four of them were alive (median follow\u2010up: 7\u00a0years).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MIITOP showed acceptable tolerability in this heavily pretreated population and encouraging survival rates in VHR\u2010NBL when followed by busulfan\u2010melphalan.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.30615","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T05:54:01Z","timestamp":1691992441000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Phase II study of <sup>131<\/sup>I\u2010metaiodobenzylguanidine with 5\u00a0days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOP"],"prefix":"10.1002","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8824-2729","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Sevrin","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology Oscar Lambret Center  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Kolesnikov\u2010Gauthier","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Oscar Lambret Center  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Cougnenc","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Oscar Lambret Center  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Bogart","sequence":"additional","affiliation":[{"name":"Department of Methodology and Biostatistics Oscar Lambret Center  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0133-5879","authenticated-orcid":false,"given":"Gudrun","family":"Schleiermacher","sequence":"additional","affiliation":[{"name":"SIREDO Integrated Pediatric Oncology Center Institut Curie  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Courbon","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Nucl\u00e9aire Institut Universitaire du Cancer de Toulouse Oncopole  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Gambart","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Unit Children's Hospital, CHU Toulouse  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2010Laure","family":"Giraudet","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine L\u00e9on B\u00e9rard Center  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"Corradini","sequence":"additional","affiliation":[{"name":"Institute of Pediatric Hematology and Oncology L\u00e9on B\u00e9rard Center  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010No\u00ebl","family":"Badel","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine L\u00e9on B\u00e9rard Center  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwann","family":"Rault","sequence":"additional","affiliation":[{"name":"Department of Medical Physics Oscar Lambret Center Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Oudoux","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Oscar Lambret Center  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C\u00e9cile Le","family":"Deley","sequence":"additional","affiliation":[{"name":"Department of Methodology and Biostatistics Oscar Lambret Center  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Valteau\u2010Couanet","sequence":"additional","affiliation":[{"name":"Department of Childhood and Adolescent Oncology Gustave\u2010Roussy  Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4277-9871","authenticated-orcid":false,"given":"Anne\u2010Sophie","family":"Defachelles","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology Oscar Lambret Center  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30070-0"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.8925"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.10014"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2017.1402997"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30355-8"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00203"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.10002"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90375-1"},{"issue":"3","key":"e_1_2_9_10_1","first-page":"705","article-title":"Radiolabeled metaiodobenzylguanidine (MIBG) in diagnosis and therapy of neuroblastoma \u2010 results from basic research (review)","volume":"6","author":"Bruchelt G","year":"1995","journal-title":"Int J Oncol"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.3484"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.229"},{"issue":"4","key":"e_1_2_9_13_1","first-page":"220","article-title":"Therapeutic use of [131I]metaiodobenzylguanidine in neuroblastoma: a phase II study in 26 patients. \u201cSoci\u00e9t\u00e9 Fran\u00e7aise d'Oncologie P\u00e9diatrique\u201d and Nuclear Medicine Co\u2010investigators","volume":"35","author":"Lumbroso J","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199206000-00009"},{"issue":"4","key":"e_1_2_9_15_1","first-page":"244","article-title":"Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma","volume":"35","author":"Matthay KK","year":"1991","journal-title":"J Nucl Biol Med"},{"issue":"4","key":"e_1_2_9_16_1","first-page":"216","article-title":"Treatment of neuroblastoma with [131I]metaiodobenzylguanidine: long\u2010term results in 25 patients","volume":"35","author":"Klingebiel T","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.06.010"},{"issue":"4","key":"e_1_2_9_18_1","first-page":"224","article-title":"[131I]metaiodobenzylguanidine therapy in advanced neuroblastoma","volume":"35","author":"Claudiani F","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200310000-00005"},{"issue":"4","key":"e_1_2_9_20_1","first-page":"202","article-title":"[131I]metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma","volume":"35","author":"Hoefnagel CA","year":"1991","journal-title":"J Nucl Biol Med"},{"issue":"1","key":"e_1_2_9_21_1","first-page":"77","article-title":"Role of 131I\u2010metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan","volume":"44","author":"Castellani MR","year":"2000","journal-title":"Q J Nucl Med"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.11.016"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1684\/bdc.2011.1353"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25200"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.7628"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6400"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1645"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3201"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1259\/bjr\/27723093"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2005.20.195"},{"issue":"4","key":"e_1_2_9_31_1","first-page":"395","article-title":"High\u2010dose 131i\u2010MIBG therapies in children: feasibility, patient dosimetry and radiation exposure to workers and family caregivers","volume":"173","author":"Cougnenc O","year":"2017","journal-title":"Radiat Prot Dosimetry"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.0177"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24713"},{"issue":"4","key":"e_1_2_9_34_1","first-page":"232","article-title":"The use of [131I]metaiodobenzylguanidine in the treatment of neuroblastoma after conventional therapy","volume":"35","author":"Troncone L","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6694223"},{"issue":"7","key":"e_1_2_9_36_1","first-page":"1140","article-title":"Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters","volume":"34","author":"Glowniak JV","year":"1993","journal-title":"J Nucl Med"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0982"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.12"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00703"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.07.023"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.647361"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/ped4.12216"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24351"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.264"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.30615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T13:05:15Z","timestamp":1695647115000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.30615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,13]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1002\/pbc.30615"],"URL":"https:\/\/doi.org\/10.1002\/pbc.30615","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,13]]},"assertion":[{"value":"2023-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e30615"}}